GeneReach Biotechnology (4171) — Financial Flexibility Index
GeneReach Biotechnology (4171) has a Financial Flexibility Index of 0.06x as of December 2025. Free cash flow of NT$16.62 Million (operating CF NT$12.05 Million minus capex NT$4.58 Million) represents 0% of total liabilities (NT$284.34 Million). Also explore GeneReach Biotechnology (4171) equity growth momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GeneReach Biotechnology Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for GeneReach Biotechnology across 9 annual periods. Check GeneReach Biotechnology strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for GeneReach Biotechnology (2017–2025)
Year-by-year free cash flow to debt coverage for GeneReach Biotechnology. For the full company profile including market capitalisation, see GeneReach Biotechnology (4171) total market value.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.01x | NT$-1.88 Million | NT$-13.52 Million | NT$284.34 Million | ▲ +84.7% |
| 2024 | -0.04x | NT$-14.76 Million | NT$-23.22 Million | NT$341.00 Million | ▼ -20.0% |
| 2023 | -0.04x | NT$-11.32 Million | NT$-38.67 Million | NT$313.71 Million | ▼ -104.7% |
| 2022 | 0.78x | NT$402.54 Million | NT$357.63 Million | NT$519.23 Million | ▲ +26.7% |
| 2021 | 0.61x | NT$364.78 Million | NT$348.99 Million | NT$596.35 Million | ▼ -0.2% |
| 2020 | 0.61x | NT$234.69 Million | NT$169.82 Million | NT$382.75 Million | ▲ +4297.5% |
| 2019 | 0.01x | NT$2.34 Million | NT$-11.19 Million | NT$167.82 Million | ▼ -33.7% |
| 2018 | 0.02x | NT$8.05 Million | NT$5.74 Million | NT$382.68 Million | ▲ +225.0% |
| 2017 | -0.02x | NT$-5.93 Million | NT$-6.83 Million | NT$352.21 Million | — |